Table 1.

Cox Regression Analysis of the DDR Pathway Signature in 545 Patients in the Pooled Validation Cohorts

Characteristic	BCR-free Survival		Metastasis-free Survival		Overall Survival
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
UVA	1.89 (1.44–2.48)	5.01E-06	1.88 (1.33–2.67)	3.91E-04	1.90 (1.32–2.72)	5.15E-04
MVA
DDR pathway signature (high risk vs low risk)	1.71 (1.29–2.28)	<.001	1.56 (1.08–2.25)	.02	1.69 (1.16–2.47)	.006
Age	0.99 (0.97–1.01)	.21	0.99 (0.96–1.02)	.45	1.02 (0.99–1.05)	.20
PSA
<10 (Low risk)	1 [Reference]		1 [Reference]		1 [Reference]
10–20 (Intermediate risk)	1.47 (1.07–2.02)	.02	1.21 (0.80–1.84)	.37	0.87 (0.57–1.34)	.53
>20 (High risk)	1.83 (1.26–2.66)	.001	1.78 (1.09–2.91)	.02	1.31 (0.78–2.18)	.31
Gleason score
6 (Low risk)	1 [Reference]		1 [Reference]		1 [Reference]
7 (Intermediate risk)	1.97 (0.98–3.94)	.06	8.84 (1.21–64.60)	.03	0.98 (0.47–2.07)	.96
8–10 (High risk)	3.77 (1.85–7.70)	<.001	19.98 (2.71–147.35)	.003	2.06 (0.96–0.42)	.06
SMS, + vs −	1.13 (0.84–1.51)	.42	1.14 (0.79–1.64)	.49	1.30 (0.89–1.90)	.18
SVI	1.55 (1.16–2.09)	.003	1.46 (1.00–2.11)	.05	1.07 (0.73–1.57)	.72
ECE	1.44 (1.04–2.00)	.03	1.64 (1.04–2.57)	.03	1.54 (0.97–2.45)	.07
LNI	0.64 (0.38–1.07)	.09	1.07 (0.59–1.94)	.81	1.31 (0.68–2.54)	.42

Abbreviations: BCR, biochemical recurrence; DDR, DNA damage and repair; ECE, extracapsular extension; HR, hazard ratio; LNI, lymph node involvement; MVA, multivariate analysis; PSA, prostate-specific antigen; SMS, surgical margin status; SVI, seminal vesicle invasion; UVA, univariate analysis.